Drug Research
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the Coalition for Epidemic Preparedness Innovations (CEPI) awarded an...
News
Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced achievement of full patient enrollment in its Phase...
IT & Data Management
J&J Launches Heartline , Virtual Study Designed to Explore if a New iPhone App and Apple Watch Can Help Reduce the Risk of Stroke
Johnson & Johnson announced that the Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Apple, opened enrollment for the Heartline™ Study. The...
Clinical Trials
Bellerophon Announces Agreement with the FDA on its Planned Pivotal Phase 3 Study for the Treatment of Pulmonary Hypertension
Bellerophon Therapeutics, Inc , a clinical-stage biotherapeutics company, announced the successful completion of its End-of-Phase 2 Meetings with the U.S. FDA for INOpulse for...
Press Releases
IBM Summit supercomputer joins fight against COVID-19
Technology has been at the center of scientific advances for decades. Just 16 years ago, IBM’s Blue Gene supercomputer debuted as the first supercomputer...
Clinical Trials
Clinerion and iClusion partner to boost the identification and recruitment of more patients into clinical trials
Clinerion’s Patient Network Explorer and iClusion’s Trial Eye platforms both connect clinical trial sponsors with networks of partner hospitals, giving trial managers the ability...
IT & Data Management
Beijing University of Chinese Medicine collaborates with Elsevier to launch first branch of traditional Chinese medicine taxonomy
Elsevier, a global leader in information analytics, specializing in science and health, launched the first branch of its Traditional Chinese Medicine (TCM) taxonomy in...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read